AMGEN INC

Amgen insider Derek Miller buys at deep discounts and sells at higher prices, signaling bullish confidence amid strong earnings and a solid pipeline.

Amgen insider buys: R&D EVP James E. purchases 3,337 shares amid positive buzz and a bullish outlook—signals confidence in Amgen’s pipeline and future gains.

Amgen insider sale by EVP Santos Esteban shows routine liquidity moves, not distress, amid a bullish pipeline and solid cash flow.

Amgen insider trading snapshot: CTO David Reese sold 6,022 shares at $366.21. Routine equity program, no change in confidence—portfolio rebalancing, not a red flag.

Amgen insider sale by EVP & Gen. Counsel Graham Jonathan P shows routine trading, not a confidence dip; stock remains strong amid pipeline growth.

Amgen insider Santos Esteban sells 5,621 shares at $366.21—no panic signal, just routine liquidity; executives stay invested, signaling long‑term confidence.

Amgen insider Busch sells 327 shares at $366.21—routine vesting, not a red flag, reinforcing long‑term confidence in the company’s pipeline.

Amgen insider sales reveal a strategic realignment: modest, liquidity‑driven trades amid broader executive buying, signaling confidence in future growth.

Bradway’s $156.35 Amgen buy shows insider confidence at a discount, hinting at value for long‑term biotech investors.

Amgen insiders keep buying shares, boosting investor confidence amid biotech resilience—learn why execs are adding stake and what it means for your portfolio.